Vinpocetine-Sar, 0.5%, 2 ml, 10 pcs.

Vinpocetine-Sar improves brain metabolism by increasing glucose and oxygen consumption by brain tissues. Increases resistance of brain cells to hypoxia by facilitating transport of oxygen and substrates of energy supply to tissues (due to decreased affinity of red blood cells, increased absorption and metabolism of glu goat, switching it to the energetically more favorable aerobic direction).

Promotes the accumulation of cyclic adenosine monophosphate and adenosine triphosphate in tissues (inhibition of calcium ions – dependent FDE and stimulation of adenylate cyclase), increases catecholamine content in brain tissues. Stimulates the ascending branch of the noradrenergic system, has an antioxidant effect.

The vasodilatory action is associated with a direct relaxant effect on the vascular smooth muscle mainly of the brain. Vinpocetine does not cause the phenomenon of “stealing”; it increases the blood supply to the ischemic area of the brain without changing the blood supply to intact areas. It improves microcirculation in the brain by reducing platelet aggregation, decreasing blood viscosity, increasing the deformability of red blood cells.

Enhances cerebral blood flow; reduces cerebral vascular resistance without significant effect on indicators of systemic circulation (blood pressure (BP), ME, heart rate).

Pharmacokinetics

Therapeutic concentration with parenteral administration in plasma is 10-20 mg/ml, the volume of distribution is 5.3 L/kg. It easily penetrates through histohematic barriers (including the blood-brain barrier). It penetrates into breast milk (0.25% during the first hour), through the placental barrier.

The half-life of the drug is 4.74-5 hours. It is excreted by the kidneys and the intestine in a ratio of 3:2. Protein binding is 66%, clearance is 66.7 l/h, exceeding liver plasma volume (50 l/h), which indicates extrahepatic metabolism.

Indications

– acute (when parenteral administration is impossible) and chronic forms of cerebral circulatory insufficiency (including. acute and residual stages of stroke, transient ischemic attacks, encephalopathies, dementia after suffered cerebrovascular disorders);
– vascular diseases of the retina and/or the cornea (due to atherosclerosis, angiospasm, thrombosis); degenerative changes in the macula caused by atherosclerosis or angiospasm; secondary glaucoma (due to vascular occlusion);
– age-related vascular or toxic (drug) hearing impairment, Meniere’s disease, vertigo of labyrinthine origin;
– vegetative manifestations of menopausal syndrome.

Active ingredient

Vinpocetine

Composition

100 ml of concentrate for preparation of solution for infusion contains:

the active ingredient:

Vinpocetine-0,5 g

excipients:

ascorbic acid,

amber acid,

p>sodium disulfite,

sodium chloride,

water for injection up to 100 ml

How to take, the dosage

Intravenously by drip (infusion rate should not exceed 80 drops/min). Initial daily dose is 20 mg (in 0.5-1 liters of 0.9% sodium chloride solution or solutions containing dextrose).

The average daily dose at body weight of 70 kg is 50 mg. In case of good tolerance within 2-3 days the dose is increased to a maximum of 1 mg/kg/day. The course of treatment should be 10-14 days. Parenteral administration is usually used in acute cases until clinical picture improves, then the drug is taken in tablet form. Subcutaneous administration of the drug is not allowed.

In case of improvement we start taking the drug orally.

Interaction

Concentrate for preparation of solution for infusion is pharmaceutically incompatible with heparin, solutions containing amino acids.

A hypotensive effect may be increased with methyldopa (BP control is required).

While there is no data to support the possibility of interaction, caution is recommended when using concomitantly with drugs (medications) affecting the central nervous system, antiarrhythmic agents and anticoagulants.

.

Special Instructions

In case of initial QT interval prolongation and concomitant use with QT interval prolonging drugs, periodic ECG monitoring is required during vinpocetine treatment.

When using the drug, caution should be exercised when driving vehicles and operating complex mechanisms.

.

Contraindications

• Hypersensitivity,
• acute phase of hemorrhagic stroke,
• severe coronary heart disease (CHD),
• severe heart rhythm disorders,
• pregnancy,
• lactation period,
• under 18 years of age.

With caution

With caution, use the drug in arrhythmia, angina pectoris, unstable blood pressure and decreased vascular tone. In hemorrhagic cerebral stroke parenteral administration of vinpocetine is allowed only after the acute effects have subsided – usually after 5 to 7 days

Side effects

Cardiovascular system: electrocardiogram changes (ST-segment depression, QT interval prolongation); tachycardia, extrasystole (cause-effect relationship not established), DE lability (often decreased).

Central nervous system disorders: sleep disturbances (insomnia, increased sleepiness); dizziness, headache, general weakness (may be a manifestation of the underlying disease).

In the digestive system: dry mouth, nausea, heartburn.

Others: skin allergic reactions, increased sweating, skin hyperemia, phlebitis when administered intravenously.

.

Overdose

Vinpocetine overdose may be accompanied by an increase in dose-dependent side effects of the drug. Treatment consists of the use of hypotensive and antiarrhythmic drugs under medical supervision.

.

Pregnancy use

Vinpocetine-Sar is contraindicated in pregnancy and lactation.

.

Similarities

Vinpocetine, Cavinton, Cavinton Forte, Cavinton Comfort